Dr Jinhui Xue speaks to ecancer about the final overall survival results from the BECOME study evaluating becotarug in combination with osimertinib in patients with EGFR exon 20 insertion–positive non-small cell lung cancer previously treated with platinum-based therapy.

The combination demonstrated encouraging survival outcomes, with a median overall survival of 18 months.

Subgroup analyses revealed differences based on insertion location, with patients harbouring far-loop insertions experiencing improved survival compared to other subtypes.

Additionally, baseline circulating tumour DNA status was associated with outcomes, with ctDNA-negative patients showing longer progression-free and overall survival.

These findings provide important insights into patient selection and the biology underlying response, supporting further development of this combination in this difficult-to-treat population.